Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3-diones, and 2-aminopyridazino[3,4-a]pyrrolo[3,4-c]carbazole-1,3,4,7-tetraone

European Journal of Medicinal Chemistry

Volumn 43, Issue 2, 2008, Pages 282-292

  Conchon, Elisabeth ^a   Anizon, Fabrice ^a   Aboab, Bettina ^a   Golsteyn, Roy M ^b   Léonce, Stéphane ^b   Pfeiffer, Bruno ^b   Prudhomme, Michelle ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

2 Amino pyridazino 3,4 a pyrrolo 3,4 c carbazole 1,3,4,7 tetraone; Antitumor agents; Chk1 inhibitors; Pyrrolo 3,4 a carbazole 1,3 diones

Indexed keywords

2 AMINOPYRIDAZINO[3,4 A]PYRROLO[3,4 C]CARBAZOLE 1,3,4,7 TETRAONE; ADENOSINE TRIPHOSPHATE; CARBAZOLE DERIVATIVE; CHECKPOINT KINASE 1; GLUTAMINE; HETEROCYCLIC COMPOUND; IMIDE; NITROGEN; PYRIDAZINONE DERIVATIVE; PYRROLE DERIVATIVE; PYRROLO[3,4 A]CARBAZOLE 1,3 DIONE DERIVATIVE; PYRROLO[3,4 C]CARBAZOLE 1,3 DIONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; INHIBITION KINETICS; LEUKEMIA L 1210; MURINE LEUKEMIA; NONHUMAN; TUMOR CELL LINE;

ANIMALS; CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED;

EID: 38949095649     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2007.03.026     Document Type: Article

References (31)

1. Anderson H.J., Andersen R.J., and Roberge M. In: Meijer L., Jézéquel A., and Roberge M. (Eds). Prog. Cell Cycle Res. 5 (2003) 423-430
2. Prudhomme M. Recent Pat. Anti-Cancer Drug Discovery 1 (2006) 55-68
3. Bartek J., and Lukas J. Cancer Cell 3 (2003) 421-429
4. Tao Z.F. Anticancer Agents Med. Chem. 6 (2006) 377-388
5. Berlinck R.G.S., Britton R., Piers E., Lim L.Y., Roberge M., Moreira da Rocha R., and Andersen R.J. J. Org. Chem. 63 (1998) 9850-9856
6. Roberge M., Berlinck R.G.S., Xu L., Anderson H.J., Lim L.Y., Curman D., Stringer C.M., Friend S.H., Davies P., Vincent I., Haggarty S.J., Kelly M.T., Britton R., Piers E., and Andersen R.J. Cancer Res. 58 (1998) 5701-5706
7. R.J. Andersen, M. Roberge, J. Sanghera, D. Leung, PCT. Int. Appl. WO99/47522, 1999. Chem. Abstr. 131:243451.
8. Jiang X., Zhao B., Britton R., Lim L.Y., Leong D., Sanghera J.S., Zhou B.B.S., Piers E., Andersen R.J., and Roberge M. Mol. Cancer Ther. 3 (2004) 1221-1227
9. Piers E., Britton R., and Andersen R.J. J. Org. Chem. 65 (2000) 530-535
10. Zhao B., Bower M.J., McDevitt P.J., Zhao H., Davis S.T., Johanson K.O., Green S.M., Concha N.O., and Zhou B.B.S. J. Biol. Chem. 277 (2002) 46609-46615
11. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Tetrahedron Lett. 44 (2003) 3935-3937
12. Hugon B., Pfeiffer B., Renard P., and Prudhomme M. Tetrahedron Lett. 44 (2003) 3927-3930
13. Hénon H., Messaoudi S., Hugon B., Anizon F., Pfeiffer B., and Prudhomme M. Tetrahedron 61 (2005) 5599-5614
14. Hénon H., Anizon F., Pfeiffer B., and Prudhomme M. Tetrahedron 62 (2006) 1116-1123
15. Hénon H., Anizon F., Kucharczyk N., Loynel A., Casara P., Pfeiffer B., and Prudhomme M. Synthesis 4 (2006) 711-715
16. Hénon H., Anizon F., Golsteyn R.M., Léonce S., Hofmann R., Pfeiffer B., and Prudhomme M. Bioorg. Med. Chem. 14 (2006) 3825-3834
17. Hénon H., Anizon F., Aboab B., Kucharczyk N., Léonce S., Golsteyn R.M., Pfeiffer B., and Prudhomme M. Eur. J. Pharmacol. 554 (2007) 106-112
18. Conchon E., Anizon F., Golsteyn R., Léonce S., Pfeiffer B., and Prudhomme M. Tetrahedron 62 (2006) 11136-11144
19. Conchon E., Aboab B., Golsteyn R., Léonce S., Pfeiffer B., and Prudhomme M. Eur. J. Med. Chem. 41 (2006) 1470-1477
20. Knölker H.J., and Hitzemann R. Tetrahedron Lett. 35 (1994) 2157-2160
21. Wenkert E., Moeller P.D.R., and Piettre S.R. J. Am. Chem. Soc. 110 (1988) 7188-7194
22. Bailly C., Qu X., Anizon F., Prudhomme M., Riou J.F., and Chaires J.B. Mol. Pharmacol. 55 (1999) 377-385
23. Rodrigues Pereira E., Fabre S., Sancelme M., Prudhomme M., and Rapp M. J. Antibiot. 48 (1995) 863-868
24. Rodrigues Pereira E., Belin L., Sancelme M., Prudhomme M., Ollier M., Rapp M., Sevère D., Riou J.F., Fabbro D., and Meyer T. J. Med. Chem. 39 (1996) 4471-4477
25. F. Anizon, PhD thesis, Université de Clermont-Ferrand, France, DU No 1162, 1999.
26. See Belstein 24, 373.
27. Davies S.P., Reddy H., Caivano M., and Cohen P. Biochem. J. 351 (2000) 95-105
28. Macromodel 8.0, Shroedinger Inc, 1500 SW First Ave. Suite 1180, Portland, OR 97201, USA.
29. Weiner S.J., Kollman P.A., Case A.D., Singh U.C., Ghio C., Alagona G., Profeta S., and Weiner P. J. Am. Chem. Soc. 106 (1984) 765-784
30. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.M., and Kollman P.A. J. Am. Chem. Soc. 117 (1995) 5179-5197
31. Léonce S., Pérez V., Casabianca-Pignède M.R., Anstett M., Bisagni E., and Atassi G. Invest. New Drugs 14 (1996) 169-180